SEATTLE, June 27, 2022 /PRNewswire/ — According to Consistent market informationthe US opioid market is estimated at US$16,285.2 million in 2022 and should present a CAGR of 5.5% during the forecast period (2022-2030).
Key Trends and Analysis of the US Opioid Market:
Regulatory agencies are taking steps towards developing non-addictive alternatives to opioids to manage acute pain, reduce exposure to opioids, and prevent re-addiction, which is expected to affect market growth. For example, in February 2022, the U.S. Food and Drug Administration has taken new steps to encourage the development of non-addictive alternatives to opioids to manage acute pain and reduce opioid exposure and prevent re-addiction. The agency released draft guidelines to provide recommendations for companies developing nonopioid pain relievers for acute pain lasting up to 30 days, usually in response to some form of tissue damage, such as trauma or surgery. These guidelines support the U.S. Department of Health and Human Services (HHS) Overdose Prevention Strategy, which focuses on four priority areas including primary prevention, harm reduction, evidence-based treatment, and prevention. aid in recovery.
Request a sample copy of this report from https://www.coherentmarketinsights.com/insight/request-sample/1048
Main market takeaways:
The US opioid market is expected to show a CAGR of 5.5% over the forecast period due to the increasing prevalence of migraine and the subsequent use of opioids to overcome pain. For example, according to an article published by the journal Neurology, in August 2020of 2,388 respondents with migraine using prescription medication for acute treatment, 36.3% reported using or keeping opioid medication on hand to treat headache in the United States
Among the drug types, Hydrocodone segment is expected to lead the segment growth over the forecast period, owing to its increased usage for pain management. For example, according to data provided by ClinCalc, a website providing clinical decision support tools and calculators for healthcare professionals, the estimated number of prescriptions for acetaminophen and hydrocodone in the United States in 2019 was around 30,355,778.
Based on therapeutic application, the pain management segment is expected to lead the segment growth over the forecast period, owing to the increasing prevalence of chronic pain. For example, according to data provided by the Pain Doctor, a website that educates people about their pain conditions and treatment options, in 2018, 100 million people in the United States suffered from chronic pain.
Key players operating in the US Opioids market include Purdue Pharmaceuticals LP, Titan Pharmaceuticals, Inc., Pfizer Inc., MallinckrodtPfizer Inc., Assertio Holdings, Inc., Par Pharmaceutical, Amneal Pharmaceuticals LLC, Trevena, Inc., Lupine and Endo Pharmaceuticals, Inc.
Customization request at https://www.coherentmarketinsights.com/insight/request-customization/1048
U.S. Opioid Market, By Drug:
U.S. Opioid Market, By Therapeutic Application:
- pain management
- Neuropathic pain
- Back ache
- Osteoarthritis pain
- Cancer pain
- Cough treatment
- Treatment of diarrhea
U.S. opioid market, by distribution channel:
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Buy this full report now at https://www.coherentmarketinsights.com/insight/buy-now/1048
Find the related trend report below:
Opioids marketby drug type (codeine, fentanyl, morphine, hydrocodone, oxycodone, and others), by application (analgesia, cough suppression, and diarrhea suppression), by route of administration (oral, topical, parenteral, and others), by distribution channel (hospital pharmacies, retail pharmacies and online pharmacies), and by region (North America, Latin America, Europe, Asia Pacific, Middle Eastand Africa) – Size, Share, Prospects & Opportunities Analysis, 2021 – 2028
Consistent market information is a global market intelligence and advisory organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office at Indiahaving a sales office in the financial capital of the world in the United States and sales advisers in UK and Japan. Our customer base includes players from various industries in more than 57 countries around the world. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leading role in providing insight in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.
Mr. Raj Shah
Senior Client Partner – Business Development
Consistent market information
E-mail: [email protected]
Follow us: LinkedIn | Twitter
SOURCE Consistent Market Information